Glutamine and Whey Protein Improve Intestinal Permeability and Morphology in Patients with Crohn's Disease: a Randomized Controlled Trial

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2011 Nov 1

PMID 22038507

Citations 40

Authors

Jaya Benjamin

Govind Makharia

Vineet Ahuja

K D Anand Rajan

Mani Kalaivani

Siddhartha Datta Gupta

Yogendra Kumar Joshi

Affiliations

Soon will be listed here.

Abstract

Background: Increased intestinal permeability (IP) has been implicated in the etiopathogenesis, disease activity and relapse of Crohn's disease (CD). Glutamine, the major fuel for the enterocytes, may improve IP.

Aim: We evaluated the effect of oral glutamine on IP and intestinal morphology in patients with CD.

Methods: In a randomized controlled trial, consecutive patients with CD in remission phase with an abnormal IP were randomized to a glutamine group (GG) or active control group (ACG) and were given oral glutamine or whey protein, respectively, as 0.5 g/kg ideal body weight/day for 2 months. IP was assessed by the lactulose mannitol excretion ratio (LMR) in urine, and morphometry was performed by computerized image analysis system.

Results: Patients (age 34.5 ± 10.5 years; 20 males) were assigned to the GG (n = 15) or ACG (n = 15). Fourteen patients in each group completed the trial. The LMR [median (range)] in GG and ACG at 2 months was 0.029 (0.006-0.090) and 0.033 (0.009-0.077), respectively, with P = 0.6133. IP normalized in 8 (57.1%) patients in each group (P = 1.000). The villous crypt ratio (VCR) [mean (SD)] in GG and ACG at 2 months was 2.68 (1.02) and 2.49 (0.67), respectively, (P = 0.347). At the end of 2 months LMR improved significantly in GG from 0.071 (0.041-0.254) to 0.029 (0.006-0.090) (P = 0.0012) and in ACG from 0.067 (0.040-0.136) to 0.033 (0.009-0.077) (P = 0.0063). VCR improved in the GG from 2.33 (0.77) to 2.68 (1.02) (P = 0.001), and in ACG from 2.26 (0.57) to 2.49 (0.67) (P = 0.009).

Conclusions: Intestinal permeability and morphology improved significantly in both glutamine and ACG.

Citing Articles

Nutritional Management in Stricturing Crohn's Disease: A Pilot Study.

Cavalcanti E, Marra A, Mileti A, Donghia R, Curlo M, Mastronardi M Nutrients. 2024; 16(23.

PMID: 39683547 PMC: 11644502. DOI: 10.3390/nu16234153.

The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases.

Posta E, Fekete I, Varkonyi I, Zold E, Barta Z Cells. 2024; 13(20.

PMID: 39451206 PMC: 11505700. DOI: 10.3390/cells13201688.

A systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on gut permeability in adults.

Abbasi F, Haghighat Lari M, Khosravi G, Mansouri E, Payandeh N, Milajerdi A Amino Acids. 2024; 56(1):60.

PMID: 39397201 PMC: 11471693. DOI: 10.1007/s00726-024-03420-7.

Leaky Gut Syndrome: Myths and Management.

Lacy B, Wise J, Cangemi D Gastroenterol Hepatol (N Y). 2024; 20(5):264-272.

PMID: 39193076 PMC: 11345991.

The Effect of Protein Nutritional Support on Inflammatory Bowel Disease and Its Potential Mechanisms.

Li Q, Wang J Nutrients. 2024; 16(14).

PMID: 39064745 PMC: 11280054. DOI: 10.3390/nu16142302.

References

Behrens R, Docherty H, Elia M, Neale G . A simple enzymatic method for the assay of urinary lactulose. Clin Chim Acta. 1984; 137(3):361-7. DOI: 10.1016/0009-8981(84)90125-6. View

van der Hulst R, Von Meyenfeldt M, Tiebosch A, Buurman W, Soeters P . Glutamine and intestinal immune cells in humans. JPEN J Parenter Enteral Nutr. 1997; 21(6):310-5. DOI: 10.1177/0148607197021006310. View

Bingham S, Gill C, Welch A, Day K, Cassidy A, Khaw K . Comparison of dietary assessment methods in nutritional epidemiology: weighed records v. 24 h recalls, food-frequency questionnaires and estimated-diet records. Br J Nutr. 1994; 72(4):619-43. DOI: 10.1079/bjn19940064. View

Choi K, Lee S, Oh S, Lim S, Lim S, Jeon W . The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr. 2006; 26(1):57-62. DOI: 10.1016/j.clnu.2006.07.003. View

Sukhotnik I, Khateeb K, Mogilner J, Helou H, Lurie M, Coran A . Dietary glutamine supplementation prevents mucosal injury and modulates intestinal epithelial restitution following ischemia-reperfusion injury in the rat. Dig Dis Sci. 2007; 52(6):1497-504. DOI: 10.1007/s10620-006-9629-8. View

Li J, Langkamp-Henken B, Suzuki K, Stahlgren L . Glutamine prevents parenteral nutrition-induced increases in intestinal permeability. JPEN J Parenter Enteral Nutr. 1994; 18(4):303-7. DOI: 10.1177/014860719401800404. View

Juby L, Dixon M, Axon A . Abnormal intestinal permeability and jejunal morphometry. J Clin Pathol. 1987; 40(7):714-8. PMC: 1141086. DOI: 10.1136/jcp.40.7.714. View

Scheppach W, Dusel G, Kuhn T, Loges C, Karch H, Bartram H . Effect of L-glutamine and n-butyrate on the restitution of rat colonic mucosa after acid induced injury. Gut. 1996; 38(6):878-85. PMC: 1383196. DOI: 10.1136/gut.38.6.878. View

Rhoads J, Wu G . Glutamine, arginine, and leucine signaling in the intestine. Amino Acids. 2009; 37(1):111-22. DOI: 10.1007/s00726-008-0225-4. View

10.

Buchman A, Moukarzel A, Bhuta S, Belle M, Ament M, Eckhert C . Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. JPEN J Parenter Enteral Nutr. 1995; 19(6):453-60. DOI: 10.1177/0148607195019006453. View

11.

Noyer C, Simon D, Borczuk A, Brandt L, Lee M, Nehra V . A double-blind placebo-controlled pilot study of glutamine therapy for abnormal intestinal permeability in patients with AIDS. Am J Gastroenterol. 1998; 93(6):972-5. DOI: 10.1111/j.1572-0241.1998.00290.x. View

12.

Den Hond E, Hiele M, Peeters M, Ghoos Y, Rutgeerts P . Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr. 1999; 23(1):7-11. DOI: 10.1177/014860719902300107. View

13.

Peeters M, Ghoos Y, Maes B, Hiele M, Geboes K, VANTRAPPEN G . Increased permeability of macroscopically normal small bowel in Crohn's disease. Dig Dis Sci. 1994; 39(10):2170-6. DOI: 10.1007/BF02090367. View

14.

van der Hulst R, Von Meyenfeldt M, van Kreel B, Thunnissen F, Brummer R, Arends J . Gut permeability, intestinal morphology, and nutritional depletion. Nutrition. 1998; 14(1):1-6. DOI: 10.1016/s0899-9007(97)00385-7. View

15.

Soderholm J, Olaison G, Lindberg E, Hannestad U, Vindels A, Tysk C . Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence?. Gut. 1998; 44(1):96-100. PMC: 1760070. DOI: 10.1136/gut.44.1.96. View

16.

McKeehan W . Glycolysis, glutaminolysis and cell proliferation. Cell Biol Int Rep. 1982; 6(7):635-50. DOI: 10.1016/0309-1651(82)90125-4. View

17.

Ksiazyk J, Piena M, Kierkus J, Lyszkowska M . Hydrolyzed versus nonhydrolyzed protein diet in short bowel syndrome in children. J Pediatr Gastroenterol Nutr. 2002; 35(5):615-8. DOI: 10.1097/00005176-200211000-00005. View

18.

Boza J, Jimenez J, Baro L, Martinez O, Suarez M, Gil A . Effects of native and hydrolyzed whey protein on intestinal repair of severely starved rats at weaning. J Pediatr Gastroenterol Nutr. 1996; 22(2):186-93. DOI: 10.1097/00005176-199602000-00010. View

19.

Demarco V, Li N, Thomas J, West C, Neu J . Glutamine and barrier function in cultured Caco-2 epithelial cell monolayers. J Nutr. 2003; 133(7):2176-9. DOI: 10.1093/jn/133.7.2176. View

20.

Sanderson I, Boulton P, Menzies I, Walker-Smith J . Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. Gut. 1987; 28(9):1073-6. PMC: 1433221. DOI: 10.1136/gut.28.9.1073. View